The Covifenz COVID-19 vaccine (plant-based virus-like particles (VLP), recombinant, adjuvanted) is a plant-based vaccine developed in partnership by Medicago and GlaxoSmithKline which is approved in Canada for the prevention of COVID-19.L40694 It is composed of VLPs expressing SARS-CoV-2 spike protein trimers (stabilized in a pre-fusion conformation) and is mixed with the AS03 adjuvant system prior to administration.L40694
While the concept of plant-based VLPs as vaccines is not new,A245824 it is a novel approach to COVID-19 vaccination, with previously approved COVID-19 vaccines mostly comprising viral vector (e.g. the AstraZeneca COVID-19 vaccine) and nucleic acid vaccines (e.g. the Moderna COVID-19 vaccine).A245819 Plant-based VLPs offer a number of advantages as compared to other vaccine platforms, including speed and ease of manufacturing and increased immunogenicity.A245824 In addition, VLPs contain no viral material and are therefore inherently non-infectious, making them potentially safer alternatives to traditional vaccines.A245824
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.